Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P220034/S008

LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus

DiaSorin, Inc. · Decision date Dec 19, 2025

FDA DECISIONP220034/S008

What did the FDA decide?

FDA records P220034/S008 as a supplement to PMA P220034, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 19, 2025.

FDA approval order statement

a new supplier has been added for DiaSorins accessory
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Microbiology
Decision date
Dec 19, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P220034/S008
Regulatory pathway
PMA supplement
Product code
MYL
Decision code
OK30
Decision date
Dec 19, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: ASSAY,ENZYME LINKED IMMUNOSORBENT,PARVOVIRUS B19 IGG.

Product code
MYL
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P220034/S007 · Related supplement

    LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus

  2. P220034/S008 received

    Application receipt date recorded by FDA.

  3. P220034/S008 · FDA decision

    30-Day Notice

  4. P220034/S011 · Related supplement

    LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus

  5. P220034/S010 · Related supplement

    LIAISON Biotrin Parvovirus B19 IgG Plus; LIAISON Biotrin Control Parvovirus B19 IgG Plus

Timeline entries are records held by MedtechLedger for P220034. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220034

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

DiaSorin, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1951 Northwestern Ave., Stillwater, MN, 55082

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records